Literature DB >> 19830439

FUS pathology in basophilic inclusion body disease.

David G Munoz1, Manuela Neumann, Hirofumi Kusaka, Osamu Yokota, Kenji Ishihara, Seishi Terada, Shigetoshi Kuroda, Ian R Mackenzie.   

Abstract

Basophilic Inclusion Body Disease (BIBD) is a tau-negative form of frontotemporal lobar degeneration (FTLD), characterized by neuronal cytoplasmic inclusions (NCI) that are visible on hematoxylin and eosin stain (HE), contain RNA, and are inconsistently ubiquitin-immunoreactive (ir). The normal nuclear expression of TDP-43 is not altered. Here we investigate whether the distribution of the structurally and functionally related protein fused in sarcoma (FUS) is altered in BIBD. Mutations in the FUS gene have recently been identified as a cause of familial amyotrophic lateral sclerosis (ALS). In addition to these familial ALS cases, FUS protein has recently been demonstrated in NCI in a subset of FTLD with ubiquitinated inclusions (atypical FTLD-U) and in neuronal intermediate filament inclusion disease (NIFID). We examined seven BIBD brains of patients with average age at onset 46 (range 29-57) and average duration of disease 8 years (range 5-12). Three cases presented with the behavioural variant of fronto-temporal dementia (FTD-bv) and one with FTD-bv combined with severe dysarthria. All four developed motor neuron disease/ALS syndrome (MND/ALS) several years later. In the other three cases, presentation was predominantly with motor symptoms, construed as MND/ALS in two, and progressive supranuclear palsy (PSP) in one. Severity of cortical degeneration varied, but all cases shared severe nigrostriatal atrophy and lower motor neuron pathology. In spared areas of cortex, FUS antibodies showed intense labelling of neuronal nuclei and weak positivity of cytoplasm, whereas, in affected areas, intense labelling of NCI was accompanied by reduction or disappearance of the normal IR pattern. The number of FUS-ir NCI was much greater than the number detected by HE or with ubiquitin or P62 immunohistochemistry. FUS-ir glial cytoplasmic inclusions (GCI) were abundant in the grey and white matter in all cases, whereas neuronal intranuclear inclusions were rare and only seen in 2/7 cases. Thus, BIBD shares with atypical FTLD-U and NIFID the presence of FUS-ir NCI and GCI, and together comprise a new biochemical category of neurodegenerative disease (FUS proteinopathies). The consistent involvement of motorneurons in BIBD indicates that the association of FTLD and MND/ALS can occur on a FUS or TDP-43 pathological substrate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830439     DOI: 10.1007/s00401-009-0598-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  95 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

3.  Caudate atrophy on MRI is a characteristic feature of FTLD-FUS.

Authors:  K A Josephs; J L Whitwell; J E Parisi; R C Petersen; B F Boeve; C R Jack; D W Dickson
Journal:  Eur J Neurol       Date:  2010-03-03       Impact factor: 6.089

Review 4.  Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.

Authors:  Daisuke Ito; Norihiro Suzuki
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

Review 5.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

6.  Clinical characterization of bvFTD due to FUS neuropathology.

Authors:  Suzee E Lee; William W Seeley; Pardis Poorzand; Rosa Rademakers; Anna Karydas; Christine M Stanley; Bruce L Miller; Katherine P Rankin
Journal:  Neurocase       Date:  2011-11-07       Impact factor: 0.881

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 8.  Amyotrophic lateral sclerosis: an update on recent genetic insights.

Authors:  Yohei Iguchi; Masahisa Katsuno; Kensuke Ikenaka; Shinsuke Ishigaki; Gen Sobue
Journal:  J Neurol       Date:  2013-10-02       Impact factor: 4.849

9.  Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.

Authors:  Ian R A Mackenzie; Olaf Ansorge; Michael Strong; Juan Bilbao; Lorne Zinman; Lee-Cyn Ang; Matt Baker; Heather Stewart; Andrew Eisen; Rosa Rademakers; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2011-05-21       Impact factor: 17.088

10.  FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.

Authors:  Tristan Page; Michael A Gitcho; Sabrina Mosaheb; Deborah Carter; Sumi Chakraverty; Robert H Perry; Eileen H Bigio; Marla Gearing; Isidre Ferrer; Alison M Goate; Nigel J Cairns; Julian R Thorpe
Journal:  J Mol Neurosci       Date:  2011-05-21       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.